Radiology Registry on Pancreatic Malignancies

Pancreatic Cancer Clinical Trial

— RadonPams  

Official title:

Radiology Registry on Pancreatic Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05714111
• Other study ID #: RadonPams
• Status: Recruiting
• Start date: March 4, 2022
• Est. completion date: March 30, 2030

Study information

• Verified date: April 2024
• Source: IRCCS San Raffaele
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to collect all radiological data which evaluated with clinical data may help assess malignancy and prognosis of pancreatic disease.This registry aims to collect retrospective data from 2014 and prospective data until 2027 with a maximum follow-up of 3 years per patient.

Description:

Single center, observational (retrospective and prospective) will collect all available parameters to assess the clinical outcome of the patients (progression free survival (PFS), overall survival (OS), local progression free survival LTPFS), response to treatment) with pancreatic neoplasms presenting to San Raffaele. Patient assignment to a given diagnostic and/or therapeutic procedure is not related to random assignment methods but is part of the ordinary therapeutic strategy planned for each patient on an individual basis and after multidisciplinary discussion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1300
• Est. completion date: March 30, 2030
• Est. primary completion date: March 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• =18 years of age

• Patients with suspect (planned for investigation) or diagnosed pancreatic cancer at any stage.

• able and willing to sign informed consent

Exclusion Criteria:

• Patients with non-primary pancreatic disease

Related Conditions & MeSH terms

• Pancreas Cyst
• Pancreas Disease
• Pancreas Neoplasm
• Pancreatic Cancer
• Pancreatic Cyst
• Pancreatic Diseases
• Pancreatic Neoplasms

Intervention

Other:
• Radiology evaluations and interventions
Diagnostic and interventional radiology procedures

Locations

Country	Name	City	State
Italy	Department of Radiology, IRCCS Ospedale San Raffaele	Milan

Sponsors (1)

Lead Sponsor	Collaborator
IRCCS San Raffaele

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression- free survival	Time from start of observation to disease progression	From date of intervention until the date of first documented progression, up to a maximum of 3 years
Primary	Local progression free survival	Time between (start of) a locoregional treatment and local disease progression	From date of intervention until the date of first documented local progression assessed up to a maximum of 3 years
Secondary	Overall Survival	The length of time from either the date of diagnosis or the start of treatment for a disease, in which the patients are still alive	From date of treatment until the date of death from any cause assessed up to 3 years